Research reveals new drug target urgently needed for tuberculosis therapy

One third of the world is infected with the bacterium that causes tuberculosis (TB), a disease that is increasingly difficult to treat because of wide spread resistance to available drugs. Researchers from the Institute of Pharmacology and Structural Biology (CNRS, Université de Toulouse) in Toulouse (France) have identified a fresh target to develop new drugs for TB. The study, published in the Open Access journal PLOS Pathogens, shows why the target will be important in developing new TB treatments.

The deadliest form of human tuberculosis is caused by Mycobacterium tuberculosis (M.tb). The burden of infection continues to increase and every year the world sees 8 million new cases and nearly 2 million deaths. TB, which occurs mostly in developing countries (including China, India and Brazil), drastically hinders economic growth. Current tuberculosis treatments are nearly 50 years old, take more than six months to complete and have many side effects, which makes it difficult for people to take the full course of drugs. The treatments have also become less effective because new are resistant to multiple drugs. There is an urgent need to find drugs with new modes of action that will shorten the duration of treatment, improve ways to fight drug-resistant tuberculosis and treat dormant infections to prevent them from later developing into full blown disease.

The cell envelope of M.tb has an unusually high content of substances called lipids which have unusual composition and are known to play an important role in the causing disease. The production of these disease causing lipids was known to be controlled by the action of a protein which is the enzyme PptT in M.tb.

In this study, the researchers found that production of PptT is needed for growth of M.tb in a culture dish. It is also needed for growth and survival of M.tb in a mouse, which serves as a model for human disease. These findings are the reasons why PptT should be a very good and allow the development of against TB. The study has also developed a way to quickly test hundreds of thousands of chemical agents (aka drugs) that block the action of Ppt and growth of M.tb. This approach is important and has been used by drug companies to develop drugs to many human diseases.

More information: Leblanc C, Prudhomme T, Tabouret G, Ray A, Burbaud S, et al. (2012) 4'-Phosphopantetheinyl Transferase PptT, a New Drug Target Required for Mycobacterium tuberculosis Growth and Persistence In Vivo. PLoS Pathog 8(12): e1003097. doi:10.1371/journal.ppat.1003097

add to favorites email to friend print save as pdf

Related Stories

New tuberculosis research movement needed

Nov 30, 2011

In this week's PLoS Medicine, Christian Lienhardt from the WHO in Geneva, Switzerland and colleagues announce that the Stop TB Partnership and the WHO Stop TB Department have launched the TB Research Movement.

Drug-resistant tuberculosis rife in China

Dec 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are re ...

Recommended for you

Recorded Ebola deaths top 7,000

19 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.